经尿道前列腺汽化电切术治疗高危前列腺增生

Transurethral Vaporization for High-Risk Prostate Hyperplasia

目的探讨经尿道前列腺汽化电切术（transurethral electrovaporization of the prostate,TUVP）治疗高危前列腺增生的安全性和疗效。方法采用经尿道汽化电切术治疗高危前列腺增生90例。结果90例患者平均手术时间54min,全部患者均安全度过围手术期,术后4～5 d拔导尿管,88例排尿通畅,2例拔管后排尿困难,经再次导尿5 d拔管后排尿通畅,无尿失禁及死亡病例。随访1～24个月,国际前列腺症状评分（international prostate symptom score,IPSS）由术前平均31.2分下降至8.6分,生活质量评分（quality of life,QOL）由术前平均5.5分降至2.0分。结论经尿道前列腺汽化电切术治疗高危前列腺增生安全性高,并发症少,疗效满意。

Objective To explore the safety and efficacy of transurethral vaporization of the prostate for benign prostatic hyperplasia with high-risk. Methods Transurethral vaporization of the prostate was performed in 90 patients with high risk of prostate hyperplasia. Results The average operating time was 54 minutes. All patients were safe in the perioperative period. The catheter was pulled away at 4 to 5 days after operation. 88 cases got unobstructed micturition,2 cases received the indwelling urethral catheter again after the first catheterization because of the urination difficulties. No case of urinary incontinence and death was found. A follow-up of 2 to 24 months showed that the international prostate symptom score（IPSS） decreased from 31.2 to 8.6 points, and the score of the quality of life （QOL） decreased from 5.5 to 2.0 points. Conclusions Transurethral vaporization of the prostate is safe and effective with fewer complications for high-risk benign prostatic hyperplasia.